Kyverna Therapeutics, Inc. 8-K

What Happened
Kyverna Therapeutics, Inc. filed a Form 8-K on May 12, 2026 furnishing a press release that provides a business update and reports the company’s financial results for the quarter ended March 31, 2026. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: May 12, 2026 (Form 8-K, Item 2.02 and Item 9.01).
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Press release with results: Exhibit 99.1 to the 8-K (dated May 12, 2026).
• Report signed on behalf of the company by Marc Grasso, Chief Financial Officer.

Why It Matters
This 8-K signals that Kyverna has publicly disclosed its latest quarterly results and a business update; those results (revenue, expenses, cash position, and any commentary on development progress or guidance) are in the attached press release and can affect investor decisions and market sentiment. Retail investors should review Exhibit 99.1 for the specific financial figures and management commentary, and watch for any follow-up filings (e.g., Form 10-Q) that provide full financial statements and additional detail. Keywords: earnings, quarterly results, revenue, CFO.